Welcome to new Emergence client, Prosper Animal Health

We are happy to extend a warm “EmerGence welcome” to our newest client, Prosper Animal Health. Welcome to Canada’s bioscience incubation program!

prosper-logoProsper Animal Health (PAH) is an animal health company that is creating and commercializing a portfolio of breakthrough vaccines for multiple livestock and companion animal species.

Prosper controls an internationally patented breakthrough technology – IMT504 – that is designed to improve the effectiveness, diversity, safety, and duration of vaccines.

pah1IMT504 is a novel, first-in-class oligodeoxynucleotide (ODN) which has desirable immunostimulatory effects.

IMT504 is the prototype member of the family of non-CpG motif-containing ODNs with the generic formula PyNTTTTGT. Read more about IMT504 here!

Prosper Animal Health has initially targeted four diseases which seriously impact the animal health industry worldwide:

  • Canine (Dog) Influenza (Flu) Vaccine
  • Swine Influenza (FLU) Vaccine
  • Porcine Reproductive & Respiratory Syndrome (Swine PRRS) Vaccine
  • Johne’s (Cattle) Disease Vaccine.

PAH’s management team and its scientific advisors have acclaimed global research and clinical expertise in vaccines and infectious diseases, pharmaceutical drug development, regulatory compliance, and global pharmaceutical P&L and commercial expertise. The company’s principals have held senior level positions at leading international pharmaceutical companies over the past 30 years.

Other members of the operational and advisory teams include entrepreneurs, operational specialists, scientists, and industry experts in human and animal drug development and commercialization.

Posted in Clients, News

Welcome to new Emergence client, GenCanBio Inc.

We are happy to extend a warm “EmerGence welcome” to our newest client, GenCanBio Inc., from Nova Scotia. Welcome to Canada’s bioscience incubation program!

gencanbiologoGenCanBio is a Nova Scotia-based biotechnology company that has developed proprietary high-throughput and low-cost in vivo bioassays to screen plant compounds for a variety of indications.

This allows the company to quicly and cheaply determine which compounds show bio-activity for specific indications and to take early steps to protect associated intellectual property.

gcbA virtual drug development company, GenCanBio’s core executive team has demonstrated expertise in strategic management, drug development and commercialization, R&D project management, intellectual property and financial control.

These internal capabilities allow the company to manage contractual collaboration and outsourcing activities with some of the world’s leading government, educational and private research institutions.

GenCanBio is using its own proprietary in vivo pain and bone regeneration assays to address osteoarthritis, among other indications. The global osteoarthritis market alone is $7 billion and growing 8.5% annually. The two major existing treatments for the long term/chronic pain associated with osteoarthritis are associated with side effects including:

  • NSAIDS–gastrointestinal problems including ulcers
  • Opiates–cardiorespiratory depression and addictio

GenCanBio believes that they can address the causes as well as the symptoms of osteoarthritis with minimal or no side effects.

Click here for information about how to contact GenCanBio!

 

Posted in Clients, News

PEI Premier MacLauchlan in conversation with Emergence client, RPS Biologiques

As part of his “Island Entrepreneurs” video series, PEI Premier, Wade MacLauchlan, recently dropped in on Emergence client, RPS Biologiques. The Premier’s “Island Entrepreneurs” video series showcases PEI-based businesses and their successes. You can check out their conversation here!

 

rps-biologicsRPS Biologiques of Charlottetown, PEI, is focused on the development and commercialization of fish health products for aquaculture.

The company was incorporated in 2015 to commercialize the advanced research projects of founder and CEO Dr. Subrata Chowdhury.

RPS was announced recently as one of the successful recipients of Innovation PEI’s Ignition Startup Fund, which will help move the company’s anti-fungal product, Saprotect, toward regulatory approval and commercialization. Click here for the full story!

Saprotect was developed for the prevention and treatment of fungal infections in large scale fish farming operations. The natural product is a safe, eco-friendly and cost-effective alternative to toxic chemicals that are sometimes used against infectious microorganisms in aquaculture.

The “Island Entrepreneurs” video series is made up of short, informal videos highlight how these businesses got started, the owner’s entrepreneurial drive and how these businesses contribute to helping Prince Edward Island become the Mighty Island. (For further information about this series, please contact:  Harris Ford, Special Assistant to the Premier, Premier’s Office, Tel: (902) 368-4400, E-mail: hsford@gov.pe.ca.)

 

Posted in Clients, News

“Dragon’s Den” Charlottetown auditions announced – and you’re invited to pitch!

It’s time for Emergence clients – and all aspiring entrepreneurs – to get their business pitches polished – for a chance to be  part of DRAGONS’ DEN’s 12th  season on CBC!

ddDRAGONS’ DEN gives entrepreneurs the opportunity to pitch their businesses to a panel of wealthy Canadian business moguls – the Dragons. Successful pitchers will have a chance to earn real investment – from the Dragons’ own pockets!

Entrants should prepare to pitch their concept to the DRAGONS DEN producers in five minutes or less. If they show the producers they have what it takes to pitch in the Den, they could be invited to Toronto to face the Dragons.

In Charlottetown, auditions will take place: March 3, 10 a.m. to 5 p.m. – Charlottetown, PE at CBC PEI (430 University Avenue). Not in Charlottetown, click here for the full schedule of auditions.

Prospective pitchers are encouraged to apply online and bring a completed application form to the audition.

This is an opportunity for young and enthusiastic entrepreneurs to  pitch their business concept for the chance to appear on national television. Click here for further information!

About DRAGONS’ DEN

DRAGONS’ DEN is one of the most successful Canadian unscripted programs and is currently in its 11th season. In addition to its success on air, DRAGONS’ DEN is also a hit online, boasting an active and engaged online community and averaging more than 450,000 page views per month. Full episodes and exclusive behind-the-scenes content can be viewed at cbc.ca/dragonsden. DRAGONS’ DEN is filmed at the CBC Broadcasting Centre in Toronto and airs Wednesdays at 8 p.m. (8:30 NT) on CBC Television.

Find the show online at:

Posted in News

12 Key Do’s & Don’ts of Hiring & Firing

Emergence Partner, McInnes Cooper, recently published sage advice for companies in growth mode.

new-mcinnes-cooper-logo-300-dpi-mediumEntitled “12 Key Do’s & Don’ts of Hiring & Firing“, this piece is as relevant for early-stage and start-up ventures as it is for established companies.

McInnes Cooper writes: “The hiring process and the termination process are equally important stages of the employment relationship – and both are full of minefields for employers. It’s critical that employers put the time in both up-front to ensure they are hiring the right people in the first place, and at the back-end to ensure they are ending employment relationships in a way that complies with the law and minimizes their liability exposure.

Here are their 12 “key” do’s and don’ts for employers when hiring and firing employees.

  1. Do require all applicants to submit a (well-drafted) employment application.
  2. Do check applicant references.
  3. Don’t ask interview questions that violate human rights legislation.
  4. Do use Social Media to screen candidates.
  5. Do be careful what you say – and don’t make promises.
  6. Do use a written employment contract – before you agree on the employment terms.
  7. Do pick the right (legal) reason for the termination.
  8. Do ascertain notice and prepare the separation package in advance when termination is without cause.
  9. Do plan ahead to implement the employment termination.
  10. Don’t violate the applicable employment standards legislation.
  11. Do always terminate with dignity, or be ready to pay the price.
  12. Don’t jump the gun if an employee resigns.

You can read the full article here!

 

Posted in Clients, News, Partner, Uncategorized

Welcome to new Emergence client, Dalriada Therapeutics Inc.

We are happy to extend a warm “EmerGence welcome” to our newest client, Dalriada Therapeutics Inc., from Mississauga, Ontario. Welcome to Canada’s bioscience incubation program!

dalriadaDalriada Therapeutics Inc. is a start-up focusing on the development of novel small molecules for a range of therapeutic and diagnostic applications.

With broad expertise in drug discovery and chemosensor technologies, the company’s efforts are currently centred on the preclinical development of a novel class (DT1) of small molecule inhibitors in cancers of the blood and brain as well as proliferative skin pathologies.

Dalriada is engaged in the development of small molecule-based diagnostic technologies for Alzheimer’s disease and infections.

In addition to these R&D activities, Dalriada offers services in medicinal chemistry and custom synthesis.

Dalriada’s founders:

 

gunning

Dr. Patrick Gunning, Chief Scientific Officer, Dalriada Therapeutics Inc.

Dr. Patrick T GunningChief Scientific Officer – Patrick is a world leader in the development of small molecule inhibitors targeting the STAT3 and STAT5 oncogenes. He currently holds the rank of Full Professor and is a Canada Research Chair in Medicinal Chemistry at the University of Toronto. Patrick is the inaugural Director of Centre of Medicinal Chemistry at the University of Toronto Mississauga.

Patrick has over 100 peer-reviewed publications, presented over 120 invited lectures, and published over 140 abstracts at conferences worldwide. He is the principal inventor on 10 patent applications, with several licensed to industrial partners. Patrick is the recipient of 18 National and international awards in 9 years and his work attracted $15 million in research grants and ~$8 M in philanthropic donations.

dziyana

Dr. Diana Kraskouskaya, Chief Executive Officer, Dalriada Therapeutics, Inc.

Dr. Diana Kraskouskaya, Chief Executive Officer – With a BSc degree in molecular Biology and a PhD degree in medicinal chemistry, Diana has a broad expertise in drug discovery and 6 years of experience in the management of multi-faceted research programs.

Diana has presented at multiple research conferences, is an author of 8 research publications, and is a recipient of 19 personal awards and scholarships. For the past two years, Diana has directed the research operations of the Gunning Group, managing a team of 20 full time (post)graduate and ~ 15 rotating undergraduate staff and researchers, managed >$1.2 M yearly operating budget and directed a $7 M research infrastructure development project.

 

Posted in Clients, News

Emergence client, Delivra Corp’s LivRelief products to be distributed across Canada in single dose size

Burlington, Ontario-and Charlottetown, PEI-based Emergence client, Delivra, has announced a new distribution agreement with Spike Marks Inc. (“Spike”) for the launch of its three Over-the-Counter products in a simple and revolutionary single dose travel size.

delivra1As a result of this agreement, consumers will see new 1.5g single-use sachets of the LivRelief Pain Relief Cream, LivRelief Nerve Pain Cream and LivRelief Healing Cream available in convenience stores throughout Canada.

dr-gabriele

Dr. Joe Gabriel, CEO, Delivra

“Spike offers unparalleled access to the Canadian market, providing comprehensive and consistently outstanding service to more than 27,000 points of sale from Vancouver Island to Newfoundland. This expanded availability and distribution, give consumers a new way to sample our products,” Dr. Joseph Gabriele, Delivra’s Chief Executive Officer, told us.

“In addition, this revolutionary packaging system will be used for Delivra’s future pharmaceutical products to prevent overdosing. Delivra aims to increase brand awareness and drive sales of its larger sized products currently available in pharmacies and retail chains across the country.”

Delivra’s suite of topical creams under the “LivRelief” brand has been available in retail stores since 2012.

The new, convenient single-use packages will begin to make their way into point of purchase displays. The 25-pack displays will make their way into as many as 500 retail locations in Canada, beginning February, 2017. Their patented Easysnap packaging provides hygienic, clean ease of use for added convenience.

Delivra’s suite of products utilizes the transdermal delivery technology developed by Dr. Joseph Gabriele and his team at Delivra.

Delivra uses the innovative transdermal delivery system to deliver target relief using natural ingredients. LivRelief products provide targeted opioid-free pain relief alternatives to millions of Canadians.

ABOUT DELIVRA CORP.

Delivra Corp. is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com.

Posted in Clients, News